347 completed, 329 unknown, 239 recruiting, 105 active not recruiting. 504 Phase 2, 197 Phase 3, 185 Not applicable, 168 Phase 1, 14 Early Phase 1.
Follow Pharyngeal Neoplasms: new trials by email Literature Review of Pharyngeal Neoplasms trials Research Report on Pharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-27 | 2026-10-22 |
| Off-line Adaptive Proton Therapy Off-line Adaptive Proton Therapy (o-APT) Workflow Evaluation - Oropharyngeal Carcinoma | Not yet recruiting | University Medical Center Groningen | 100 | 2026-10-01 | 2026-10-08 | |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-09-30 | 2026-08-13 |
| Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery Intraoperative soft palate suspension using the double-strap method., Intraoperative soft palate suspension using the full-wrap method. - Adenoid Hypertrophy, Tonsillar Hypertrophy | Not applicable | Not yet recruiting | Sun Yat-sen University | 138 | 2026-09-30 | 2026-07-10 |
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers Electronic Health Record Review, Fentanyl, Laryngoscopy - Head and Neck Carcinoma, Hypopharyngeal Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 58 | 2026-09-22 | 2026-10-05 |
| A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma BL-B01D1, PD-1 monoclonal antibody, Gemcitabine - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 60 | 2026-09-01 | 2026-09-16 |
| Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma reduced dose group, Standard Dose Group, concurrent chemoradiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Fudan University | 269 | 2026-09-01 | 2026-08-27 |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer Lymphatic mapping with SPECT-CT, Bilateral neck radiotherapy, Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy - Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers | Not applicable | Not yet recruiting | UNICANCER | 128 | 2026-09-01 | 2026-07-21 |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-09-01 | 2026-08-11 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 132 | 2026-09-01 | 2026-08-14 |
| A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors BL-M08D1 - Nasopharyngeal Carcinoma (NPC), Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-09-01 | 2026-09-14 |
| A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-09-01 | 2026-09-15 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
Showing 20 of 1206. Sign in to see all of them.
Nasopharyngeal Carcinoma (645) · Oropharyngeal Neoplasms (367) · Nasopharyngeal Neoplasms (224) · Head and Neck Neoplasms (199) · Mouth Neoplasms (158) · Laryngeal Neoplasms (154) · Hypopharyngeal Neoplasms (147) · Squamous Cell Carcinoma of Head and Neck (136) · Uterine Cervical Neoplasms (52) · Carcinoma (47) · Carcinoma, Non-Small-Cell Lung (47) · Recurrence (39) · Neoplasm Metastasis (38) · Carcinoma, Squamous Cell (37) · Esophageal Neoplasms (37)
Stomatognathic Diseases (1204) · Pharyngeal Diseases (1203) · Neoplasms by Site (1201) · Otorhinolaryngologic Neoplasms (1201) · Otorhinolaryngologic Diseases (1199) · Neoplasms (1176) · Head and Neck Neoplasms (1007) · Neoplasms by Histologic Type (820) · Nasopharyngeal Diseases (816) · Neoplasms, Glandular and Epithelial (813) · Carcinoma (762) · Nasopharyngeal Neoplasms (597) · Respiratory Tract Diseases (204) · Mouth Diseases (201)
Cisplatin (229) · Radiotherapy, Intensity-Modulated (106) · Gemcitabine (96) · Radiotherapy (73) · Docetaxel (61) · Fluorouracil (54) · toripalimab (50) · Capecitabine (43) · Drug Therapy (36) · pembrolizumab (35) · Carboplatin (34) · Cetuximab (32) · Magnetic Resonance Spectroscopy (32) · Radiation (31) · camrelizumab (28)
Sun Yat-sen University (212) · National Cancer Institute (NCI) (48) · Fudan University (35) · M.D. Anderson Cancer Center (34) · Zhejiang Cancer Hospital (24) · Fujian Cancer Hospital (18) · Eye & ENT Hospital of Fudan University (14) · Jiangxi Provincial Cancer Hospital (14) · National University Hospital, Singapore (13) · Mayo Clinic (12) · Memorial Sloan Kettering Cancer Center (12) · Ming-Yuan Chen (10) · National Taiwan University Hospital (10) · Chinese University of Hong Kong (9) · Nanfang Hospital, Southern Medical University (9)
China (546) · United States (342) · France (47) · Taiwan (44) · Canada (43) · Singapore (41) · Hong Kong (26) · Italy (18) · United Kingdom (18) · Germany (17) · Spain (16) · Denmark (14) · Australia (13) · South Korea (13) · Malaysia (11)
Jun Ma, M.D. (14) · Ming-Yuan Chen, MD,PhD (11) · Ming-Yuan Chen, MD, PhD (9) · Chaosu Hu, MD (7) · Jiade J Lu, MD (6) · Fang-Yun Xie, M.D. (5) · Ming-yuan Chen, MD, PhD (5) · Yun-fei Xia, MD (5) · Chong Zhao, M.D (4) · Jian Guan, Ph.D. (4) · Li Zhang, MD (4) · Nancy Lee, MD (4) · Wei Jiang, Ph.D. (4) · Xiaozhong Chen (4) · Xiaozhong Chen, MD (4)
PMID 31150573, PMID 30207593, PMID 27686945, PMID 28837405, PMID 29584545, PMID 34341578, PMID 30213452, PMID 31178151, PMID 33492986, PMID 35240053, PMID 35997729, PMID 36746459, PMID 38507662, PMID 39970442, PMID 19564532, PMID 22154591, PMID 27567279, PMID 27567280, PMID 30620929, PMID 31536129, PMID 32017652, PMID 34111416, PMID 34174189, PMID 34990291, PMID 35355438, PMID 35709465, PMID 37207654, PMID 37409613, PMID 37537541, PMID 37580352, PMID 37801967, PMID 38520712, PMID 39438442, PMID 40692081, PMID 40890288, PMID 41791006, PMID 41813900, PMID 42032732, PMID 42580817, PMID 10623691, PMID 10640954, PMID 10811668, PMID 10924966, PMID 11212235, PMID 11224527, PMID 11375603, PMID 12646834, PMID 14511925, PMID 14520092, PMID 14710949
U10CA180868 (9), P30CA138292 (6), U10CA180820 (6), 2018 (3), 2019 (3), U10CA180821 (3), 2014 (2), 2017 (2), 2023 (2), P30CA006973 (2), P30CA012197 (2), P30CA014520 (2), P30CA015083 (2), P30CA016672 (2), P30CA023074 (2)